Mizuho restated their buy rating on shares of Celgene (NASDAQ:CELG) in a research note issued to investors on Wednesday. They currently have a $128.00 target price on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a buy rating and issued a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Robert W. Baird reaffirmed a buy rating and issued a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Vetr raised Celgene from a hold rating to a buy rating and set a $146.58 price target on the stock in a report on Friday, October 6th. Royal Bank of Canada reaffirmed a buy rating and issued a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Finally, JPMorgan Chase & Co. reaffirmed a buy rating on shares of Celgene in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $129.98.
Shares of Celgene (CELG) opened at $102.65 on Wednesday. The company has a market capitalization of $80,820.00, a P/E ratio of 24.21, a P/E/G ratio of 0.66 and a beta of 1.77. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 earnings per share. analysts expect that Celgene will post 6.71 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Grisanti Capital Management LLC purchased a new position in shares of Celgene during the 2nd quarter valued at $3,616,000. RiverPoint Capital Management LLC grew its holdings in shares of Celgene by 3.1% during the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares in the last quarter. LSV Asset Management purchased a new position in shares of Celgene during the 2nd quarter valued at $1,701,000. Spectrum Management Group Inc. purchased a new position in shares of Celgene during the 2nd quarter valued at $462,000. Finally, Polen Capital Management LLC grew its holdings in shares of Celgene by 7.7% during the 2nd quarter. Polen Capital Management LLC now owns 5,082,991 shares of the biopharmaceutical company’s stock valued at $660,128,000 after acquiring an additional 363,108 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celgene (CELG) Stock Rating Reaffirmed by Mizuho” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/21/celgene-celg-stock-rating-reaffirmed-by-mizuho.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.